Nebieridze Anano, Abu-Bakr Aya, Nazir Abubakar, Ghosson Abir, Minova Anamarija, Uwishema Olivier
Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda.
Faculty of Medicine, David Tvildiani Medical University, Tbilisi, Georgia.
Ann Med Surg (Lond). 2025 May 26;87(7):4255-4261. doi: 10.1097/MS9.0000000000003430. eCollection 2025 Jul.
Gut microbiota has a symbiotic relationship with their host. It is known that the gut microbiome has the potential to affect the host and vice versa. Cardiovascular disease and its comorbidities are the leading cause of death worldwide. Patients with various heart conditions have been observed to have a different composition of the gut microbiome. It has been postulated that the gut microbiome and its derivatives exert various effects on the cardiovascular system, termed the gut-heart axis. In this study, we aim to explore how the gut microbiome and the active metabolites produced by these microorganisms affect patient cardiovascular health. Additionally, we will discuss how gut microbiota can become a target for the new era of precision cardiology.
Data were collected through the online databases PubMed, Google Scholar, Ovid MEDLINE, and ScienceDirect. Articles regarding cardiovascular health and pathology as well as its overlap with gut microbiome and health were used.
Emerging evidence suggests that gut microbiome has a significant influence on cardiovascular disease through its metabolites, such as trimethylamine N-oxide and short-chain fatty acids, which impact cholesterol metabolism, systemic inflammation, and plaque stability. Targeting said derivatives has proven to provide beneficial results for patients suffering from cardiovascular disease.
Finding reported here highlights the importance of microbiome in cardiovascular disease and health and suggest that microbiome-based interventions hold promise for prevention and treatment of cardiovascular disease. More research needs to be conducted to study more concrete effects of specific microorganisms on cardiovascular health. Multicenter, longitudinal studies with a large sample size will provide the best evidence for clinically significant findings. Using precision cardiology, to target the gut microbiome and its derivatives, with medications like antibiotics, and nonpharmacologic interventions like lifestyle modification and fecal transplantation can positively influence cardiovascular health and help with the effective management of ongoing diseases.
肠道微生物群与其宿主存在共生关系。已知肠道微生物组有影响宿主的潜力，反之亦然。心血管疾病及其合并症是全球主要的死亡原因。已观察到患有各种心脏病的患者肠道微生物组的组成有所不同。据推测，肠道微生物组及其衍生物对心血管系统发挥各种作用，这被称为肠-心轴。在本研究中，我们旨在探讨肠道微生物组以及这些微生物产生的活性代谢产物如何影响患者的心血管健康。此外，我们将讨论肠道微生物群如何能够成为精准心脏病学新时代的一个靶点。
通过在线数据库PubMed、谷歌学术、Ovid MEDLINE和ScienceDirect收集数据。使用了关于心血管健康与病理学以及其与肠道微生物组和健康重叠方面的文章。
新出现的证据表明，肠道微生物组通过其代谢产物，如氧化三甲胺和短链脂肪酸，对心血管疾病有重大影响，这些代谢产物会影响胆固醇代谢、全身炎症和斑块稳定性。事实证明，针对上述衍生物对患有心血管疾病的患者有有益效果。
此处报告的研究结果突出了微生物组在心血管疾病和健康中的重要性，并表明基于微生物组的干预措施在预防和治疗心血管疾病方面具有前景。需要进行更多研究以探究特定微生物对心血管健康更具体的影响。多中心、大样本量的纵向研究将为具有临床意义的研究结果提供最佳证据。利用精准心脏病学，通过使用抗生素等药物以及生活方式改变和粪便移植等非药物干预措施来靶向肠道微生物组及其衍生物，可以对心血管健康产生积极影响，并有助于有效管理现有疾病。
